Liquidia (NASDAQ:LQDA) Given New $25.00 Price Target at Needham & Company LLC

Liquidia (NASDAQ:LQDA - Get Free Report) had its target price raised by Needham & Company LLC from $19.00 to $25.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Needham & Company LLC's target price would indicate a potential upside of 59.64% from the company's previous close.

LQDA has been the topic of a number of other research reports. Wells Fargo & Company began coverage on Liquidia in a report on Friday, December 20th. They issued an "overweight" rating and a $20.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $29.00 price target on shares of Liquidia in a research report on Thursday. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $26.63.

Liquidia Stock Up 3.6 %

Shares of NASDAQ LQDA traded up $0.54 during trading on Thursday, reaching $15.66. 794,613 shares of the company traded hands, compared to its average volume of 933,982. The firm has a 50 day simple moving average of $14.87 and a 200-day simple moving average of $12.27. Liquidia has a 52-week low of $8.26 and a 52-week high of $16.92. The stock has a market capitalization of $1.34 billion, a PE ratio of -9.61 and a beta of 0.07.

Remove Ads

Liquidia (NASDAQ:LQDA - Get Free Report) last issued its earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The company had revenue of $2.92 million during the quarter, compared to analysts' expectations of $4.60 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. As a group, research analysts predict that Liquidia will post -1.51 EPS for the current year.

Insider Transactions at Liquidia

In other Liquidia news, General Counsel Russell Schundler sold 16,393 shares of the stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total value of $193,109.54. Following the completion of the sale, the general counsel now owns 573,478 shares in the company, valued at approximately $6,755,570.84. This represents a 2.78 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Rajeev Saggar sold 6,249 shares of the firm's stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $73,613.22. Following the sale, the insider now directly owns 270,388 shares in the company, valued at approximately $3,185,170.64. This represents a 2.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 71,245 shares of company stock valued at $843,326 over the last quarter. 30.10% of the stock is currently owned by company insiders.

Institutional Trading of Liquidia

Institutional investors have recently made changes to their positions in the business. Intech Investment Management LLC bought a new position in Liquidia in the 3rd quarter worth approximately $195,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Liquidia by 144.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company's stock worth $3,903,000 after buying an additional 230,820 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of Liquidia by 735.1% during the third quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company's stock worth $1,402,000 after acquiring an additional 123,402 shares during the last quarter. Acuta Capital Partners LLC purchased a new position in Liquidia during the third quarter valued at $735,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Liquidia by 43.5% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,708 shares of the company's stock valued at $187,000 after acquiring an additional 5,669 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company's stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).